CytomX Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on CytomX Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how CytomX Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with CytomX Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CytomX Therapeutics Inc (CytomX) is a clinical-stage biopharmaceutical company. The company focused on developing novel conditionally activated and masked biologics. The company's product pipeline includes CX-2051 which treats Advanced metastatic colorectal cancer; CX-801 targets Advanced melanoma. CytomX utilizes PROBODY platform across the most compelling antibody therapeutic modalities such as antibody drug conjugates, T-cell-engaging bispecifics, and cytokine therapy. The company collaborates with biopharmaceutical companies. CytomX is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
151 Oyster Point Blvd., Suite 400, South San Francisco, California, 94080
Website
cytomx.com
Telephone
1 650 5153185
No of Employees
69
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CTMX (NASD)
Revenue (2024)
$76.2M
-44.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-154.5%
(2024 vs 2023)
Market Cap*
$733.7M
Net Profit Margin (2024)
XYZ
-198.7%
(2024 vs 2023)
* As of and is in US$
CytomX Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline products: | PROBODY |
| CX-2051: Advanced Metastatic Colorectal Cancer | |
| CX-801: Advanced Melanoma | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | CytomX Therapeutics Inc | AbbVie Inc | Amgen Inc | Halozyme Therapeutics Inc | Xilio Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | North Chicago | Thousand Oaks | San Diego | Waltham |
| State/Province | California | Illinois | California | California | Massachusetts |
| No. of Employees | 69 | 57,000 | 31,500 | 423 | 76 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sean A. McCarthy, D. Phil | Chief Executive Officer; Chairman | Executive Board | 2019 | 59 |
| Christopher W. Ogden | Senior Vice President; Chief Financial Officer | Senior Management | 2024 | 59 |
| Wayne Chu M.D. | Senior Vice President; Chief Medical Officer | Senior Management | 2023 | 58 |
| Marcia P. Belvin Ph.D. | Chief Scientific Officer; Senior Vice President | Senior Management | 2022 | 59 |
| Danielle Olander-Moghadassian | Consulting Chief Human Resources Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer